| Year |
Citation |
Score |
| 2023 |
Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, Isaacs JT, Li D, Lakely B, DeLucia DC, Lee JK, Schweizer MT, Lin DW, Corey E, Nelson PS, et al. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. The Prostate. PMID 37796107 DOI: 10.1002/pros.24630 |
0.555 |
|
| 2023 |
Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. The Prostate. PMID 37559436 DOI: 10.1002/pros.24606 |
0.417 |
|
| 2023 |
Isaacs JT. Consequence of evolutionary loss of seasonal breeding by humans for prostate cancer chemoprevention. American Journal of Clinical and Experimental Urology. 11: 194-205. PMID 37441442 |
0.478 |
|
| 2023 |
Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, et al. The future of patient-derived xenografts in prostate cancer research. Nature Reviews. Urology. PMID 36650259 DOI: 10.1038/s41585-022-00706-x |
0.509 |
|
| 2022 |
Patterson JC, Varkaris A, Croucher PJP, Ridinger M, Dalrymple S, Nouri M, Xie F, Varmeh S, Jonas O, Whitman MA, Chen S, Rashed S, Makusha L, Luo J, Isaacs JT, et al. Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research. PMID 36413141 DOI: 10.1158/0008-5472.CAN-22-1533 |
0.479 |
|
| 2022 |
Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, ... ... Isaacs JT, et al. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation. PMID 36194476 DOI: 10.1172/JCI162396 |
0.555 |
|
| 2022 |
Sena LA, Brennen WN, Isaacs JT. There are gremlins in prostate cancer. Nature Cancer. 3: 530-531. PMID 35624340 DOI: 10.1038/s43018-022-00381-2 |
0.558 |
|
| 2021 |
Isaacs JT, Brennen WN, Christensen SB, Denmeade SR. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. Molecules (Basel, Switzerland). 26. PMID 34946547 DOI: 10.3390/molecules26247469 |
0.444 |
|
| 2021 |
Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, Coffey M, Topiwala D, Gomes C, Ozbek B, Jones T, Rosen M, Dong L, Wiens S, Brennen WN, ... Isaacs JT, et al. Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Research. PMID 34645612 DOI: 10.1158/0008-5472.CAN-20-3607 |
0.403 |
|
| 2021 |
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33958727 DOI: 10.1038/s41388-021-01805-6 |
0.457 |
|
| 2021 |
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, ... ... Isaacs JT, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. Jci Insight. PMID 33724955 DOI: 10.1172/jci.insight.146827 |
0.493 |
|
| 2021 |
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33564077 DOI: 10.1038/s41388-021-01640-9 |
0.457 |
|
| 2020 |
Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer (Oxford, England : 1990). 144: 302-309. PMID 33383350 DOI: 10.1016/j.ejca.2020.11.043 |
0.463 |
|
| 2020 |
Brennen WN, J Thorek DL, Jiang W, Krueger TE, Antony L, Denmeade SR, Isaacs JT. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. PMID 33148078 DOI: 10.2217/imt-2020-0066 |
0.352 |
|
| 2020 |
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 32989253 DOI: 10.1038/s41388-020-01479-6 |
0.344 |
|
| 2020 |
Rogers OC, Antony L, Levy O, Joshi N, Simons BW, Dalrymple S, Rosen M, Pickering A, Lan H, Kuang H, Ranganath SH, Zheng L, Karp JM, Howard SP, Denmeade SR, ... Isaacs JT, et al. Microparticle Encapsulation of a Prostate-Targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. PMID 32943549 DOI: 10.1158/1535-7163.Mct-20-0227 |
0.642 |
|
| 2020 |
Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, et al. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Reports. 31: 107669. PMID 32460015 DOI: 10.1016/J.Celrep.2020.107669 |
0.501 |
|
| 2019 |
Isaacs JT, Brennen WN, Denmeade SR. Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine. 7: S311. PMID 32016030 DOI: 10.21037/Atm.2019.10.32 |
0.642 |
|
| 2019 |
Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, et al. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. The Prostate. PMID 31212368 DOI: 10.1002/Pros.23839 |
0.612 |
|
| 2019 |
Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan TL, Huang J, Davicioni E, An SS, Riddle RC, Thorek DL, Garraway IP, ... ... Isaacs JT, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research. PMID 31123087 DOI: 10.1158/0008-5472.Can-18-2931 |
0.39 |
|
| 2019 |
Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Translational Medicine. PMID 30925030 DOI: 10.1002/Sctm.19-0068 |
0.307 |
|
| 2019 |
Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT. Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian Journal of Urology. 6: 99-108. PMID 30775253 DOI: 10.1016/J.Ajur.2018.11.004 |
0.631 |
|
| 2019 |
Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine. PMID 30735000 DOI: 10.1002/Sctm.18-0230 |
0.464 |
|
| 2018 |
Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer? The Prostate. PMID 30488530 DOI: 10.1002/Pros.23738 |
0.608 |
|
| 2018 |
Brennen WN, Isaacs JT. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nature Reviews. Urology. PMID 30214054 DOI: 10.1038/S41585-018-0087-9 |
0.463 |
|
| 2018 |
Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, et al. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. The Prostate. PMID 30073676 DOI: 10.1002/Pros.23701 |
0.594 |
|
| 2018 |
Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine. PMID 30070053 DOI: 10.1002/Sctm.18-0024 |
0.327 |
|
| 2018 |
Isaacs JT. Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells? American Journal of Clinical and Experimental Urology. 6: 55-61. PMID 29666833 |
0.525 |
|
| 2018 |
Brennen WN, Isaacs JT. The what, when, and why of human prostate cancer xenografts. The Prostate. PMID 29575112 DOI: 10.1002/Pros.23510 |
0.592 |
|
| 2018 |
Akinboye ES, Rogers OC, Isaacs JT. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer. The Prostate. PMID 29572902 DOI: 10.1002/Pros.23494 |
0.509 |
|
| 2017 |
Brennen WN, Isaacs JT. Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy. Cancer Cell. 32: 399-401. PMID 29017052 DOI: 10.1016/J.Ccell.2017.09.011 |
0.587 |
|
| 2017 |
Isaacs JT, Brennen WN, Denmeade SR. Rationale for Bipolar Androgen Therapy (BAT) for Metastatic Prostate Cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 28820291 DOI: 10.1080/15384101.2017.1360645 |
0.611 |
|
| 2017 |
Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. PMID 28493842 DOI: 10.18632/Oncotarget.17362 |
0.602 |
|
| 2016 |
Graham MK, Principessa L, Antony L, Meeker AK, Isaacs JT. Low p16(INK4a) Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone. The Prostate. PMID 27859428 DOI: 10.1002/Pros.23276 |
0.377 |
|
| 2016 |
Nathaniel Brennen W, Nguyen H, Dalrymple SL, Reppert-Gerber S, Kim J, Isaacs JT, Hammers H. Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget. PMID 27542256 DOI: 10.18632/Oncotarget.11347 |
0.535 |
|
| 2016 |
Guedes L, Morais C, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27166397 DOI: 10.1158/1078-0432.Ccr-16-0205 |
0.563 |
|
| 2016 |
Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, ... Isaacs JT, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 91: 140-150. PMID 27019026 DOI: 10.1016/J.Biomaterials.2016.03.023 |
0.533 |
|
| 2016 |
Hedayati M, Haffner MC, Coulter J, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Dalrymple S, Isaacs JT, Santos A, Hales RK, Razavi N, Nelson WG, Yegnasubramanian S, et al. Androgen deprivation followed by acute androgen stimulation selectively sensitizes AR-positive prostate cancer cells to ionizing radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26831716 DOI: 10.1158/1078-0432.Ccr-15-1147 |
0.591 |
|
| 2016 |
Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. The Prostate. PMID 26732992 DOI: 10.1002/Pros.23145 |
0.508 |
|
| 2016 |
Pruitt FL, Brennen N, Antony L, Rosen DM, Denmeade S, Isaacs J. Abstract 2076: Albumin-linked proaerolysin based molecular grenades: A systemic therapeutic for disseminated castration resistant prostate cancer Cancer Research. 76: 2076-2076. DOI: 10.1158/1538-7445.Am2016-2076 |
0.557 |
|
| 2016 |
Brennen N, Levy O, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Billett S, Bhowmick N, Denmeade S, Karp J, Isaacs J. Abstract 2067: Attacking prostate cancer with a prodrug-doped cellular Trojan horse Cancer Research. 76: 2067-2067. DOI: 10.1158/1538-7445.Am2016-2067 |
0.613 |
|
| 2015 |
Isaacs JT. Lessons learned about prostatic transformation from the age-related methylation of 5α-reductase type 2 gene. The American Journal of Pathology. 185: 614-6. PMID 25700984 DOI: 10.1016/J.Ajpath.2015.01.001 |
0.462 |
|
| 2015 |
Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science Translational Medicine. 7: 269ra2. PMID 25568070 DOI: 10.1126/Scitranslmed.3010563 |
0.579 |
|
| 2015 |
Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB. Targeting thapsigargin towards tumors. Steroids. 97: 2-7. PMID 25065587 DOI: 10.1016/J.Steroids.2014.07.009 |
0.585 |
|
| 2014 |
Isaacs JT, Dalrymple SL, Rosen DM, Hammers H, Olsson A, Leanderson T. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 5: 8093-106. PMID 25193858 DOI: 10.18632/Oncotarget.2378 |
0.497 |
|
| 2014 |
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. 371: 1028-38. PMID 25184630 DOI: 10.1056/Nejmoa1315815 |
0.53 |
|
| 2014 |
Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. The Prostate. 74: 1308-19. PMID 25053236 DOI: 10.1002/Pros.22847 |
0.347 |
|
| 2014 |
Vander Griend DJ, Litvinov IV, Isaacs JT. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. International Journal of Biological Sciences. 10: 627-42. PMID 24948876 DOI: 10.7150/Ijbs.8756 |
0.743 |
|
| 2014 |
Antony L, van der Schoor F, Dalrymple SL, Isaacs JT. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription. The Prostate. 74: 1118-31. PMID 24913829 DOI: 10.1002/Pros.22828 |
0.433 |
|
| 2014 |
Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Research. 74: 3390-5. PMID 24747912 DOI: 10.1158/0008-5472.Can-14-0249 |
0.527 |
|
| 2014 |
Regter S, Hedayati M, Zhang Y, Zhou H, Dalrymple S, Koch CJ, Isaacs JT, DeWeese TL. Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate. The Prostate. 74: 805-10. PMID 24677180 DOI: 10.1002/Pros.22803 |
0.532 |
|
| 2014 |
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Chen Y, Roeser JC, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, et al. Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 5001-5001. DOI: 10.1200/Jco.2014.32.15_Suppl.5001 |
0.488 |
|
| 2014 |
Brennen WN, Levy O, Ranganath S, Schweizer M, Rosen M, Billet S, Bhowmick N, Denmeade S, Karp J, Isaacs J. Abstract 699: Mesenchymal stem cells (MSC) as cell-based vectors for PSA-activated proaerolysin to sites of prostate cancer Cancer Research. 74: 699-699. DOI: 10.1158/1538-7445.Am2014-699 |
0.569 |
|
| 2014 |
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Fedor HL, Lotan TL, Marzo AMD, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, et al. Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer Cancer Research. 74: 2910-2910. DOI: 10.1158/1538-7445.Am2014-2910 |
0.528 |
|
| 2014 |
Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J, Chen Y, Fedor H, Lotan T, Zheng Q, De Marzo A, Isaacs J, Isaacs W, Nadal R, Paller C, et al. Ar-V7 Splice Variant and Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Overall Survival Results Annals of Oncology. 25: v1. DOI: 10.1093/Annonc/Mdu438.23 |
0.523 |
|
| 2013 |
Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer. 20: R269-90. PMID 23975882 DOI: 10.1530/Erc-13-0151 |
0.501 |
|
| 2013 |
Isaacs JT. Cancer. Prostate cancer takes nerve. Science (New York, N.Y.). 341: 134-5. PMID 23846894 DOI: 10.1126/Science.1241776 |
0.623 |
|
| 2013 |
Michiel Sedelaar JP, Dalrymple SS, Isaacs JT. Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. The Prostate. 73: 1316-25. PMID 23775398 DOI: 10.1002/Pros.22677 |
0.36 |
|
| 2013 |
Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 4: 106-17. PMID 23362217 DOI: 10.18632/Oncotarget.805 |
0.512 |
|
| 2013 |
Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Research. 73: 1386-99. PMID 23149916 DOI: 10.1158/0008-5472.Can-12-2730 |
0.466 |
|
| 2012 |
Denmeade SR, Isaacs JT. Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget. 3: 666-7. PMID 22837432 DOI: 10.18632/Oncotarget.562 |
0.498 |
|
| 2012 |
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, ... Isaacs JT, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/Scitranslmed.3003886 |
0.487 |
|
| 2012 |
Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. The Prostate. 72: 1491-505. PMID 22396319 DOI: 10.1002/Pros.22504 |
0.557 |
|
| 2012 |
Chen S, Principessa L, Isaacs JT. Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. The Prostate. 72: 1478-89. PMID 22396312 DOI: 10.1002/Pros.22503 |
0.629 |
|
| 2012 |
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics. 11: 257-66. PMID 22323494 DOI: 10.1158/1535-7163.Mct-11-0340 |
0.325 |
|
| 2012 |
Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. The Prostate. 72: 638-48. PMID 21837778 DOI: 10.1002/Pros.21467 |
0.593 |
|
| 2012 |
Chen S, Brennen N, Brodsky RA, Cheng L, Denmeade SR, Isaacs JT. Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer Cancer Research. 72: 5699-5699. DOI: 10.1158/1538-7445.Am2012-5699 |
0.579 |
|
| 2012 |
Antony L, Dalrymple S, Gerber S, Hammers H, Kachhap S, Bjork P, Olsson A, Leanderson T, Isaacs JT. Abstract 4701: Tasquinimod suppresses the adaptive stress response within sites of prostate cancer via disrupting zinc-dependent Histone Deacetylase 4 signaling. Cancer Research. 72: 4701-4701. DOI: 10.1158/1538-7445.Am2012-4701 |
0.521 |
|
| 2012 |
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, ... Isaacs JT, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004546 |
0.542 |
|
| 2011 |
Sfanos KS, Isaacs JT. The "infectious" nature of human prostate cancer: a cautionary note. Oncotarget. 2: 281-3. PMID 21521904 DOI: 10.18632/Oncotarget.267 |
0.462 |
|
| 2011 |
Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. The Prostate. 71: 1595-607. PMID 21394741 DOI: 10.1002/Pros.21375 |
0.761 |
|
| 2010 |
Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opinion On Investigational Drugs. 19: 1235-43. PMID 20836618 DOI: 10.1517/13543784.2010.514262 |
0.565 |
|
| 2010 |
D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S, Isaacs JT. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. Plos One. 5: e11475. PMID 20628607 DOI: 10.1371/Journal.Pone.0011475 |
0.612 |
|
| 2010 |
Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. The Prostate. 70: 1600-7. PMID 20607766 DOI: 10.1002/Pros.21196 |
0.622 |
|
| 2010 |
Olsson A, Björk A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Molecular Cancer. 9: 107. PMID 20470445 DOI: 10.1186/1476-4598-9-107 |
0.518 |
|
| 2010 |
Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. The Prostate. 70: 788-96. PMID 20058238 DOI: 10.1002/Pros.21111 |
0.609 |
|
| 2010 |
Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. The Prostate. 70: 90-9. PMID 19790235 DOI: 10.1002/Pros.21043 |
0.636 |
|
| 2010 |
Williams SA, Jelinek CA, Cotter RJ, Isaacs JT, Denmeade SR. Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells Cancer Research. 70: 2326-2326. DOI: 10.1158/1538-7445.Am10-2326 |
0.613 |
|
| 2010 |
Sedelaar JM, Isaacs JT. 1290 AUTO-REGULATION OF PROSTATE CANCER CELLS AS A MECHANISM FOR CASTRATION RESISTANCE Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.874 |
0.601 |
|
| 2010 |
Hales R, Santos A, Vander Griend D, Zhang Y, Hedayati M, Isaacs J, DeWeese T. In Vivo Analysis of Androgens and Radiation Timing in Prostate Cancer Growth International Journal of Radiation Oncology*Biology*Physics. 78: S112. DOI: 10.1016/J.Ijrobp.2010.07.286 |
0.58 |
|
| 2009 |
Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins. 77: 984-93. PMID 19705489 DOI: 10.1002/Prot.22524 |
0.777 |
|
| 2009 |
Sedelaar JP, Isaacs JT. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. The Prostate. 69: 1724-9. PMID 19676093 DOI: 10.1002/Pros.21028 |
0.401 |
|
| 2009 |
Vander Griend DJ, Konishi Y, De Marzo AM, Isaacs JT, Meeker AK. Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts. The Prostate. 69: 1557-64. PMID 19562732 DOI: 10.1002/Pros.21001 |
0.429 |
|
| 2009 |
Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular Cancer Therapeutics. 8: 1340-9. PMID 19417145 DOI: 10.1158/1535-7163.Mct-08-1136 |
0.622 |
|
| 2009 |
Ishioka J, Hara S, Isaacs JT, Tomura A, Nishikawa K, Kageyama Y. Suppression of mutant androgen receptors by flutamide. International Journal of Urology : Official Journal of the Japanese Urological Association. 16: 516-21. PMID 19389135 DOI: 10.1111/J.1442-2042.2009.02284.X |
0.329 |
|
| 2009 |
LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry. 48: 3490-6. PMID 19281249 DOI: 10.1021/Bi9001858 |
0.772 |
|
| 2009 |
Christensen SB, Skytte DM, Denmeade SR, Dionne C, Møller JV, Nissen P, Isaacs JT. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anti-Cancer Agents in Medicinal Chemistry. 9: 276-94. PMID 19275521 DOI: 10.2174/1871520610909030276 |
0.628 |
|
| 2009 |
D'Antonio JM, Vander Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocrine-Related Cancer. 16: 325-32. PMID 19240183 DOI: 10.1677/Erc-08-0205 |
0.603 |
|
| 2009 |
Shelfer LF, Isaacs JT. The alchemy of Jargon: etymologies of urologic neologisms: number 1--introduction to the series. The Prostate. 69: 225-7. PMID 18991247 DOI: 10.1002/Pros.20874 |
0.323 |
|
| 2009 |
Denmeade S, Rosen D, Christensen S, Dionne C, Isaacs J. A Thapsigargin Prodrug Produces Sustained Growth Inhibition and Substantial Regression of Human Breast Cancers In Vivo with Minimal Host Toxicity. Cancer Research. 69: 5074-5074. DOI: 10.1158/0008-5472.Sabcs-09-5074 |
0.471 |
|
| 2008 |
Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Research. 68: 9703-11. PMID 19047148 DOI: 10.1158/0008-5472.Can-08-3084 |
0.564 |
|
| 2008 |
Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, Isaacs JT, Chang BL, Zheng SL, Isaacs WB, Xu J. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia (New York, N.Y.). 10: 897-907. PMID 18670647 DOI: 10.1593/Neo.08428 |
0.541 |
|
| 2008 |
Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. The Prostate. 68: 1570-81. PMID 18668523 DOI: 10.1002/Pros.20821 |
0.768 |
|
| 2008 |
LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chemistry & Biology. 15: 665-74. PMID 18635003 DOI: 10.1016/J.Chembiol.2008.05.020 |
0.78 |
|
| 2008 |
Isaacs JT. Prostate stem cells and benign prostatic hyperplasia. The Prostate. 68: 1025-34. PMID 18386293 DOI: 10.1002/Pros.20763 |
0.508 |
|
| 2008 |
Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, et al. The current state of preclinical prostate cancer animal models. The Prostate. 68: 629-39. PMID 18213636 DOI: 10.1002/Pros.20726 |
0.593 |
|
| 2008 |
Singh P, Williams SA, Shah MH, Lectka T, Pritchard GJ, Isaacs JT, Denmeade SR. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins. 70: 1416-28. PMID 17894328 DOI: 10.1002/Prot.21676 |
0.716 |
|
| 2007 |
Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biology & Therapy. 6: 1360-7. PMID 17786033 DOI: 10.4161/Cbt.6.9.4541 |
0.616 |
|
| 2007 |
Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorganic & Medicinal Chemistry. 15: 4973-84. PMID 17502149 DOI: 10.1016/J.Bmc.2007.04.029 |
0.606 |
|
| 2007 |
Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle (Georgetown, Tex.). 6: 647-51. PMID 17387277 DOI: 10.4161/Cc.6.6.4028 |
0.773 |
|
| 2007 |
Urushibara M, Ishioka J, Hyochi N, Kihara K, Hara S, Singh P, Isaacs JT, Kageyama Y. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. The Prostate. 67: 799-807. PMID 17373727 DOI: 10.1002/Pros.20542 |
0.741 |
|
| 2007 |
Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. The Prostate. 67: 790-7. PMID 17373719 DOI: 10.1002/Pros.20573 |
0.608 |
|
| 2007 |
Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. Journal of the National Cancer Institute. 99: 376-85. PMID 17341729 DOI: 10.1093/Jnci/Djk065 |
0.624 |
|
| 2007 |
Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? The Prostate. 67: 312-29. PMID 17143882 DOI: 10.1002/Pros.20531 |
0.806 |
|
| 2007 |
Urushibara M, Kageyama Y, Ishioka J, Higashi Y, Hara S, Kihara K, Singh P, Isaacs JT. 267: Effects of Steroidal and Non-Steroidal Antiandrogens on Wild-Type and Mutant Androgen Receptors The Journal of Urology. 177: 89-90. DOI: 10.1016/S0022-5347(18)30532-9 |
0.629 |
|
| 2006 |
Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 15085-90. PMID 17015840 DOI: 10.1073/Pnas.0603057103 |
0.758 |
|
| 2006 |
Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Research. 66: 9171-7. PMID 16982760 DOI: 10.1158/0008-5472.Can-06-1520 |
0.703 |
|
| 2006 |
Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate. 66: 1768-78. PMID 16955399 DOI: 10.1002/Pros.20509 |
0.507 |
|
| 2006 |
Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-Related Cancer. 13: 653-66. PMID 16954423 DOI: 10.1677/Erc.1.00797 |
0.802 |
|
| 2006 |
Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Research. 66: 8598-607. PMID 16951173 DOI: 10.1158/0008-5472.Can-06-1228 |
0.697 |
|
| 2006 |
Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Research. 66: 7509-15. PMID 16885348 DOI: 10.1158/0008-5472.Can-05-3048 |
0.605 |
|
| 2006 |
Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. The Prostate. 66: 1329-38. PMID 16835890 DOI: 10.1002/Pros.20483 |
0.719 |
|
| 2006 |
Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4072-9. PMID 16818707 DOI: 10.1158/1078-0432.Ccr-06-0184 |
0.642 |
|
| 2006 |
Hallur G, Jimeno A, Dalrymple S, Zhu T, Jung MK, Hidalgo M, Isaacs JT, Sukumar S, Hamel E, Khan SR. Benzoylphenylurea sulfur analogues with potent antitumor activity. Journal of Medicinal Chemistry. 49: 2357-60. PMID 16570932 DOI: 10.1021/Jm051261S |
0.324 |
|
| 2006 |
Søhoel H, Jensen AM, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Olsen CE, Christensen SB. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorganic & Medicinal Chemistry. 14: 2810-5. PMID 16412648 DOI: 10.1016/J.Bmc.2005.12.001 |
0.402 |
|
| 2006 |
Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. The Prostate. 66: 358-68. PMID 16302271 DOI: 10.1002/Pros.20348 |
0.595 |
|
| 2005 |
Isaacs JT. New strategies for the medical treatment of prostate cancer. Bju International. 96: 35-40. PMID 16359437 DOI: 10.1111/J.1464-410X.2005.05945.X |
0.635 |
|
| 2005 |
Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Research. 65: 9269-79. PMID 16230388 DOI: 10.1158/0008-5472.Can-04-3989 |
0.48 |
|
| 2005 |
Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. Androgens and prostate cancer: are the descriptors valid? Cancer Biology & Therapy. 4: 4-5. PMID 16052746 DOI: 10.4161/Cbt.4.1.1563 |
0.599 |
|
| 2005 |
Burnett AL, Kramer MF, Dalrymple S, Isaacs JT. Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in vitro growth of prostate cancer cells. Urology. 65: 1003-7. PMID 15882753 DOI: 10.1016/J.Urology.2004.11.033 |
0.62 |
|
| 2005 |
Pfundt R, Smit F, Jansen C, Aalders T, Straatman H, Van Der Vliet W, Isaacs J, Van Kessel AG, Schalken J. Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors Genes Chromosomes and Cancer. 43: 273-283. PMID 15834941 DOI: 10.1002/Gcc.20184 |
0.576 |
|
| 2005 |
Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. Journal of Medicinal Chemistry. 48: 3005-14. PMID 15828839 DOI: 10.1021/Jm049319A |
0.614 |
|
| 2005 |
Uzgare AR, Isaacs JT. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. The International Journal of Biochemistry & Cell Biology. 37: 707-14. PMID 15694830 DOI: 10.1016/J.Biocel.2004.11.018 |
0.618 |
|
| 2005 |
Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biology & Therapy. 4: 14-22. PMID 15662118 DOI: 10.4161/Cbt.4.1.1505 |
0.646 |
|
| 2005 |
DeWeese TL, Zhang Y, Koch C, Dalrymple S, Isaacs J. Androgen Withdrawal Fails to Induce Detectable Tissue Hypoxia in the Prostate International Journal of Radiation Oncology Biology Physics. 63. DOI: 10.1016/J.Ijrobp.2005.07.794 |
0.554 |
|
| 2004 |
Litvinov IV, Antony L, Isaacs JT. Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. The Prostate. 61: 299-304. PMID 15499637 DOI: 10.1002/Pros.20187 |
0.683 |
|
| 2004 |
Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 431: 707-12. PMID 15361885 DOI: 10.1038/nature02962 |
0.544 |
|
| 2004 |
Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Research. 64: 6190-9. PMID 15342404 DOI: 10.1158/0008-5472.Can-04-0968 |
0.574 |
|
| 2004 |
Bartsch G, Fitzpatrick JM, Schalken JA, Isaacs J, Nordling J, Roehrborn CG. Consensus statement: The role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia Bju International. 93: 27-29. PMID 15009083 DOI: 10.1111/J.1464-410X.2004.04646.X |
0.582 |
|
| 2004 |
Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. Bju International. 93: 10-5. PMID 15009080 DOI: 10.1111/J.1464-410X.2003.04634.X |
0.582 |
|
| 2004 |
Litvinov IV, Chang C, Isaacs JT. Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. The Prostate. 58: 319-24. PMID 14968432 DOI: 10.1002/Pros.20027 |
0.571 |
|
| 2004 |
Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. The Prostate. 58: 211-24. PMID 14743459 DOI: 10.1002/Pros.10360 |
0.62 |
|
| 2004 |
Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nature Medicine. 10: 26-7. PMID 14702629 DOI: 10.1038/Nm0104-26 |
0.604 |
|
| 2004 |
Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. Journal of Cellular Biochemistry. 91: 196-205. PMID 14689591 DOI: 10.1002/Jcb.10764 |
0.552 |
|
| 2004 |
Karhadkar SS, Bova GS, Isaacs J, De Marzo AM, Beachy PA, Berman DM. 597: Requirement for Autonomous Hedgehog Signal Response in Prostate Cancer Metastases Journal of Urology. 171: 158-159. DOI: 10.1016/S0022-5347(18)37859-5 |
0.58 |
|
| 2003 |
Gao AC, Lou W, Dong JT, Barrett JC, Danielpour D, Isaacs JT. Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. The Prostate. 57: 256-60. PMID 14601021 DOI: 10.1002/Pros.10309 |
0.365 |
|
| 2003 |
Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? The Journal of Clinical Endocrinology and Metabolism. 88: 2972-82. PMID 12843129 DOI: 10.1210/Jc.2002-022038 |
0.764 |
|
| 2003 |
Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute. 95: 990-1000. PMID 12837835 DOI: 10.1093/Jnci/95.13.990 |
0.656 |
|
| 2003 |
Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate. 56: 45-53. PMID 12746846 DOI: 10.1002/Pros.10213 |
0.762 |
|
| 2003 |
Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate. 54: 249-57. PMID 12539223 DOI: 10.1002/Pros.10199 |
0.637 |
|
| 2003 |
Isaacs JT. From the Editor: Rapid Communications in the Prostate Prostate. 57: 255. DOI: 10.1002/Pros.10310 |
0.533 |
|
| 2002 |
Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 12: 2459-61. PMID 12161157 DOI: 10.1016/S0960-894X(02)00433-X |
0.62 |
|
| 2002 |
Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature Reviews. Cancer. 2: 389-96. PMID 12044015 DOI: 10.1038/Nrc801 |
0.611 |
|
| 2002 |
Tombal B, Denmeade SR, Gillis JM, Isaacs JT. A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death and Differentiation. 9: 561-73. PMID 11973614 DOI: 10.1038/Sj.Cdd.4400999 |
0.323 |
|
| 2002 |
Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Research. 62: 986-9. PMID 11861369 |
0.689 |
|
| 2001 |
Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. Journal of Medicinal Chemistry. 44: 4696-703. PMID 11741487 DOI: 10.1021/Jm010985A |
0.509 |
|
| 2001 |
Chen C, Brabham WW, Stultz BG, Frierson HF, Barrett JC, Sawyers CL, Isaacs JT, Dong JT. Defining a common region of deletion at 13q21 in human cancers. Genes, Chromosomes & Cancer. 31: 333-44. PMID 11433524 DOI: 10.1002/Gcc.1152 |
0.51 |
|
| 2001 |
Denmeade SR, Lövgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. The Prostate. 48: 122-6. PMID 11433422 DOI: 10.1002/Pros.1088 |
0.491 |
|
| 2001 |
Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. The Prostate. 48: 71-8. PMID 11433417 DOI: 10.1002/Pros.1083 |
0.556 |
|
| 2001 |
Gao J, Isaacs JT. Mixed lineage kinase (MLK) family members are not involved in androgen regulation of prostatic proliferation or apoptosis Prostate. 48: 67-70. PMID 11433416 DOI: 10.1002/Pros.1082 |
0.627 |
|
| 2001 |
Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Rapid communication: Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models Prostate. 48: 1-6. PMID 11391681 DOI: 10.1002/Pros.1075 |
0.635 |
|
| 2001 |
Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system Cell Death and Differentiation. 8: 192-200. PMID 11313721 DOI: 10.1038/Sj.Cdd.4400797 |
0.591 |
|
| 2001 |
Denmeade SR, Tombal B, Isaacs JT. Apoptotic pathways in prostate cancer Advances in Cell Aging and Gerontology. 6: 23-54. DOI: 10.1016/S1566-3124(01)06002-3 |
0.496 |
|
| 2001 |
Isaacs JT. The Prostate: Editorial Prostate. 46: 1. DOI: 10.1002/1097-0045(200101)46:1<1::Aid-Pros1001>3.0.Co;2-B |
0.609 |
|
| 2000 |
Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. The Prostate. 45: 350-4. PMID 11102961 DOI: 10.1002/1097-0045(20001201)45:4<350::Aid-Pros10>3.0.Co;2-U |
0.566 |
|
| 2000 |
Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT. Rational basis for Trk inhibition therapy for prostate cancer. The Prostate. 45: 140-8. PMID 11027413 DOI: 10.1002/1097-0045(20001001)45:2<140::Aid-Pros8>3.0.Co;2-# |
0.764 |
|
| 2000 |
Isaacs JT. Apoptosis: Translating theory to therapy for prostate cancer Journal of the National Cancer Institute. 92: 1367-1369. PMID 10974062 DOI: 10.1093/Jnci/92.17.1367 |
0.56 |
|
| 2000 |
Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells Prostate. 43: 303-317. PMID 10861750 DOI: 10.1002/1097-0045(20000601)43:4<303::Aid-Pros10>3.0.Co;2-V |
0.685 |
|
| 1999 |
Brøgger Christensen S, Andersen A, Kromann H, Treiman M, Tombal B, Denmeade S, Isaacs JT. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells Bioorganic and Medicinal Chemistry. 7: 1273-1280. PMID 10465403 DOI: 10.1016/S0968-0896(99)00074-7 |
0.596 |
|
| 1999 |
Epner DE, Sawa A, Isaacs JT. Glyceraldehyde-3-phosphate dehydrogenase expression during apoptosis and proliferation of rat ventral prostate. Biology of Reproduction. 61: 687-91. PMID 10456846 DOI: 10.1095/Biolreprod61.3.687 |
0.542 |
|
| 1999 |
Isaacs JT. The biology of hormone refractory prostate cancer: Why does it develop? Urologic Clinics of North America. 26: 263-273. PMID 10361549 DOI: 10.1016/S0094-0143(05)70066-5 |
0.593 |
|
| 1999 |
Denmeade SR, Lin XS, Tombal B, Isaacs JT. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. The Prostate. 39: 269-79. PMID 10344216 DOI: 10.1002/(Sici)1097-0045(19990601)39:4<269::Aid-Pros7>3.0.Co;2-F |
0.491 |
|
| 1999 |
Gao J, Tombal B, Isaacs JT. Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts Prostate. 39: 67-70. PMID 10221269 DOI: 10.1002/(Sici)1097-0045(19990401)39:1<67::Aid-Pros11>3.0.Co;2-6 |
0.405 |
|
| 1999 |
Tombal B, Denmeade SR, Isaacs JT. Assessment and validation of a microinjection method for kinetic analysis of [Ca2+](i) in individual cells undergoing apoptosis Cell Calcium. 25: 19-28. PMID 10191957 DOI: 10.1054/Ceca.1998.0005 |
0.325 |
|
| 1999 |
Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett C, Isaacs JT. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2 Prostate. 38: 46-54. PMID 9973109 DOI: 10.1002/(Sici)1097-0045(19990101)38:1<46::Aid-Pros6>3.0.Co;2-9 |
0.558 |
|
| 1999 |
Nihei N, Ohta S, Kuramochi H, Kugoh H, Oshimura M, Barrett JC, Isaacs JT, Igarashi T, Ito H, Masai M, Ichikawa Y, Ichikawa T. Metastasis suppressor gene(s) for rat prostate cancer on the long arm of human chromosome 7 Genes Chromosomes and Cancer. 24: 1-8. PMID 9892102 DOI: 10.1002/(Sici)1098-2264(199901)24:1<1::Aid-Gcc1>3.0.Co;2-A |
0.502 |
|
| 1999 |
Glassman DT, Chon JK, Borkowski A, Isaacs JT, Jacobs SC, Kyprianou N. Effect Of Finasteride And Terazosin On Apoptotic And Proliferative Indices In Benign Prostatic Hyperplasia The Journal of Urology. 226. DOI: 10.1097/00005392-199904010-00905 |
0.606 |
|
| 1998 |
Suzuki H, Dong JT, Gao AC, Barrett JC, Isaacs JT. Identification of the rat homologue of KAI1 and its expression in dunning rat prostate cancers Prostate. 37: 253-260. PMID 9831222 DOI: 10.1002/(Sici)1097-0045(19981201)37:4<253::Aid-Pros7>3.0.Co;2-3 |
0.554 |
|
| 1998 |
Joseph IBJK, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents Journal of the National Cancer Institute. 90: 1648-1653. PMID 9811314 DOI: 10.1093/Jnci/90.21.1648 |
0.443 |
|
| 1998 |
George DJ, Suzuki H, Bova GS, Isaacs JT. Mutational analysis of the TrkA gene in prostate cancer Prostate. 36: 172-180. PMID 9687989 DOI: 10.1002/(Sici)1097-0045(19980801)36:3<172::Aid-Pros5>3.0.Co;2-J |
0.594 |
|
| 1997 |
Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. The Prostate. 33: 201-7. PMID 9365549 DOI: 10.1002/(Sici)1097-0045(19971101)33:3<201::Aid-Pros9>3.0.Co;2-L |
0.541 |
|
| 1997 |
Hartley-Asp B, Vukanovic J, Joseph IBJK, Strandgården K, Polacek J, Isaacs JT. Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer Journal of Urology. 158: 902-907. PMID 9258116 DOI: 10.1016/S0022-5347(01)64361-1 |
0.42 |
|
| 1997 |
Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, Yatani R, Imai T, Dong JT, Yoshie O, Barrett JC, Isaacs JT, Shimazaki J, Ito H, Ichikawa T. Location of KAI1 on the short arm of human chromosome II and frequency of allelic loss in advanced human prostate cancer Prostate. 32: 205-213. PMID 9254900 DOI: 10.1002/(Sici)1097-0045(19970801)32:3<205::Aid-Pros7>3.0.Co;2-J |
0.553 |
|
| 1997 |
Denmeade SR, McCloskey DE, Joseph IBJK, Hahm HA, Isaacs JT, Davidson NE. Apoptosis in Hormone-Responsive Malignancies Advances in Pharmacology. 41: 553-583. PMID 9204159 DOI: 10.1016/S1054-3589(08)61072-8 |
0.554 |
|
| 1997 |
Dong JT, Isaacs WB, Barrett JC, Isaacs JT. Genomic organization of the human KAI1 metastasis-suppressor gene Genomics. 41: 25-32. PMID 9126478 DOI: 10.1006/Geno.1997.4618 |
0.321 |
|
| 1997 |
Dong JT, Isaacs WB, Isaacs JT. Molecular advances in prostate cancer Current Opinion in Oncology. 9: 101-107. PMID 9090501 DOI: 10.1097/00001622-199701000-00016 |
0.605 |
|
| 1997 |
Denmeade SR, Isaacs JT. Prostate cancer: Where are we and where are we going? British Journal of Urology, Supplement. 79: 2-7. PMID 9088266 DOI: 10.1111/J.1464-410X.1997.Tb00794.X |
0.629 |
|
| 1996 |
Isaacs JT. The R-3327 system of rat prostatic cancers. Urologic Oncology-Seminars and Original Investigations. 2: 115-116. PMID 21224150 DOI: 10.1016/S1078-1439(97)82842-6 |
0.569 |
|
| 1996 |
Bosland MC, Chung LW, Greenberg NM, Ho SM, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research A minireview. Urologic Oncology. 2: 99. PMID 21224146 DOI: 10.1016/S1078-1439(96)00077-4 |
0.562 |
|
| 1996 |
Gao AC, Isaacs JT. Expression of homeobox gene-GBX2 in human prostatic cancer cells Prostate. 29: 395-398. PMID 8977637 DOI: 10.1002/(Sici)1097-0045(199612)29:6<395::Aid-Pros8>3.0.Co;2-7 |
0.535 |
|
| 1996 |
Denmeade SR, Isaacs JT. Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer Advances in Pharmacology. 35: 281-306. PMID 8920208 DOI: 10.1016/S1054-3589(08)60278-1 |
0.641 |
|
| 1996 |
Dong JT, Rinker-Schaeffer CW, Ichikawa T, Barrett JC, Isaacs JT. Prostate cancer - biology of metastasis and its clinical implications World Journal of Urology. 14: 182-189. PMID 8806197 DOI: 10.1007/Bf00186898 |
0.653 |
|
| 1996 |
Rinker-Schaeffer CW, Wharam JF, Simons J, Isaacs JT. Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme β-galactosidase Prostate. 29: 60-64. PMID 8685057 DOI: 10.1002/(Sici)1097-0045(199607)29:1<60::Aid-Pros9>3.0.Co;2-M |
0.372 |
|
| 1996 |
Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. The Prostate. 28: 251-65. PMID 8602401 DOI: 10.1002/(Sici)1097-0045(199604)28:4<251::Aid-Pros6>3.0.Co;2-G |
0.576 |
|
| 1996 |
Denmeade SR, Isaacs JT. Programmed cell death (apoptosis) and cancer chemotherapy Cancer Control. 3: 303-309. DOI: 10.1177/107327489600300401 |
0.314 |
|
| 1996 |
Ichikawa T, Nihei N, Kuramochi H, Kawana Y, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT, Kugoh H, Oshimura M, Shimazaki J. Metastasis suppressor genes for prostate cancer. The Prostate. 6: 31-35. DOI: 10.1002/(Sici)1097-0045(1996)6+<31::Aid-Pros7>3.0.Co;2-N |
0.425 |
|
| 1995 |
Furuya Y, Isaacs JT, Shimazaki J. Induction of programmed death/apoptosis in androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal Japanese Journal of Cancer Research. 86: 1159-1165. PMID 8636004 DOI: 10.1111/J.1349-7006.1995.Tb03309.X |
0.418 |
|
| 1995 |
RINKER-SCHAEFFER CW, HAWKINS AL, SU SL, ISRAELI RS, GRIFFIN CA, ISAACS JT, HESTON WDW. Localization and Physical Mapping of the Prostate-Specific Membrane Antigen (PSM) Gene to Human Chromosome 11 Genomics. 30: 105-108. PMID 8595888 DOI: 10.1006/Geno.1995.0019 |
0.505 |
|
| 1995 |
Nihei N, Ichikawa T, Kawana Y, Kuramochi H, Kugo H, Oshimura M, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT, Shimazaki J. Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10 Genes Chromosomes and Cancer. 14: 112-119. PMID 8527392 DOI: 10.1002/Gcc.2870140205 |
0.454 |
|
| 1995 |
Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 Science. 268: 884-886. PMID 7754374 DOI: 10.1126/Science.7754374 |
0.568 |
|
| 1995 |
Furuya Y, Lin XS, Walsh JC, Nelson WG, Isaacs JT. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology. 136: 1898-906. PMID 7720636 DOI: 10.1210/Endo.136.5.7720636 |
0.571 |
|
| 1995 |
Vukanovic J, Hartley-Asp B, Isaacs JT. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers Prostate. 26: 235-246. PMID 7538663 DOI: 10.1002/Pros.2990260503 |
0.502 |
|
| 1995 |
Furuya Y, Cisekand L, Isaacs JT. MECHANISM OF PROGRAMMED DEATH OF NON-PROLIFERATING ANDROGENINDEPENDENT PROSTATIC CANCER CELLS INDUCED BY THAPSIGARGIN The Japanese Journal of Urology. 86: 349. DOI: 10.5980/Jpnjurol.86.349 |
0.566 |
|
| 1994 |
Furuya Y, Isaacs JT. Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology. 133: 2660-6. PMID 8243289 DOI: 10.1210/Endo.133.6.8243289 |
0.562 |
|
| 1994 |
Isaacs JT. Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer. Current Opinion in Oncology. 6: 82-9. PMID 8204696 DOI: 10.1097/00001622-199401000-00012 |
0.314 |
|
| 1994 |
Furuya Y, Isaacs JT. Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation Prostate. 25: 301-309. PMID 7997434 DOI: 10.1002/Pros.2990250604 |
0.396 |
|
| 1994 |
Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells Prostate. 25: 249-265. PMID 7971516 DOI: 10.1002/Pros.2990250505 |
0.638 |
|
| 1994 |
Isaacs JT. Role of androgens in prostatic cancer Vitamins and Hormones. 49: 433-502. PMID 7810075 DOI: 10.1016/S0083-6729(08)61152-8 |
0.634 |
|
| 1994 |
Isaacs JT. Etiology of benign prostatic hyperplasia. European Urology. 6-9. PMID 7507055 DOI: 10.1159/000475324 |
0.521 |
|
| 1993 |
Rinker-Schaeffer CW, Isaacs WB, Isaacs JT. Molecular and cellular markers for metastatic prostate cancer. Cancer Metastasis Reviews. 12: 3-10. PMID 8448825 DOI: 10.1007/Bf00689785 |
0.616 |
|
| 1993 |
Isaacs JT. Prostatic cancer: an overview. Cancer Metastasis Reviews. 12: 1-2. PMID 8448821 DOI: 10.1007/Bf00689784 |
0.629 |
|
| 1993 |
Levine B, Huang Q, Isaacs JT, Reed JC, Griffin DE, Hardwick JM. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature. 361: 739-42. PMID 8441470 DOI: 10.1038/361739A0 |
0.304 |
|
| 1993 |
Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proceedings of the National Academy of Sciences of the United States of America. 90: 8910-4. PMID 8415631 DOI: 10.1073/Pnas.90.19.8910 |
0.484 |
|
| 1993 |
Isaacs JT. Prostatic cancer: an age-old problem. Advances in Experimental Medicine and Biology. 330: 167-84. PMID 8368132 DOI: 10.1007/978-1-4615-2926-2_13 |
0.574 |
|
| 1993 |
Isaacs JT. Hormonal balance and the risk of prostatic cancer. Journal of Cellular Biochemistry. Supplement. 107-8. PMID 1289665 DOI: 10.1002/Jcb.240501224 |
0.581 |
|
| 1993 |
Berges R, Isaacs JT. Programming events in the regulation of cell proliferation and death. Clinical Chemistry. 39: 356-361. DOI: 10.1093/Clinchem/39.2.356 |
0.371 |
|
| 1992 |
Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology. 130: 685-94. PMID 1733716 DOI: 10.1210/Endo.130.2.1733716 |
0.594 |
|
| 1992 |
Lamb JC, Levy MA, Johnson RK, Isaacs JT. Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. The Prostate. 21: 15-34. PMID 1641369 DOI: 10.1002/Pros.2990210103 |
0.486 |
|
| 1992 |
Passaniti A, Isaacs JT, Haney JA, Adler SW, Cujdik TJ, Long PV, Kleinman HK. Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix International Journal of Cancer. 51: 318-324. PMID 1568798 DOI: 10.1002/Ijc.2910510224 |
0.442 |
|
| 1992 |
Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS. Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility Prostate. 20: 233-241. PMID 1374181 DOI: 10.1002/Pros.2990200308 |
0.466 |
|
| 1992 |
Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. Journal of Andrology. 13: 457-464. DOI: 10.1002/J.1939-4640.1992.Tb00337.X |
0.578 |
|
| 1991 |
Morton RA, Isaacs JT, Isaacs WB. Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. The Prostate. 17: 327-36. PMID 2251224 DOI: 10.1002/Pros.2990170408 |
0.566 |
|
| 1991 |
Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology. 127: 2963-8. PMID 2249636 DOI: 10.1210/Endo-127-6-2963 |
0.54 |
|
| 1991 |
Tjota A, Lee MT, Isaacs JT, Kadohama N, Lee CL. Murine monoclonal antibodies reactive with a variety of androgen independent Dunning rat prostate adenocarcinoma sublines also reactive with human prostate adenocarcinoma. The Journal of Urology. 146: 205-12. PMID 2056591 DOI: 10.1016/S0022-5347(17)37753-4 |
0.497 |
|
| 1991 |
Björk P, Isaacs JT, Hartley-Asp B. Estramustine binding protein (EMBP) in rat R3327 Dunning tumors: partial characterization and effect of hormonal withdrawal, hormonal replacement, and cytotoxic treatment on its expression. The Prostate. 18: 181-200. PMID 2020618 DOI: 10.1002/Pros.2990180302 |
0.458 |
|
| 1991 |
Juniewicz PE, Fetrow N, Marinelli J, Wolf M, Young E, Lamb J, Isaacs JT. Evaluation of Win 49,596, a novel steroidal androgen receptor antagonist, in animal models of prostate cancer. The Prostate. 18: 105-15. PMID 2006117 DOI: 10.1002/Pros.2990180203 |
0.521 |
|
| 1991 |
Steinberg GD, Brendler CB, Squire RA, Isaacs JT. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model Journal of Urology. 145: 647-653. PMID 1997724 DOI: 10.1016/S0022-5347(17)38413-6 |
0.328 |
|
| 1991 |
Kyprianou N, Alexander RB, Isaacs JT. Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. Journal of the National Cancer Institute. 83: 346-50. PMID 1847434 DOI: 10.1093/Jnci/83.5.346 |
0.309 |
|
| 1991 |
Bussemakers MJG, Isaacs JT, Debruyne FMJ, Van de Ven WJM, Schalken JA. Oncogene expression in prostate cancer World Journal of Urology. 9: 58-63. DOI: 10.1007/Bf00184034 |
0.622 |
|
| 1990 |
Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Molecular Endocrinology (Baltimore, Md.). 3: 1515-22. PMID 2608047 DOI: 10.1210/Mend-3-10-1515 |
0.522 |
|
| 1990 |
Kyprianou N, Isaacs JT. "Thymineless" death in androgen-independent prostatic cancer cells. Biochemical and Biophysical Research Communications. 165: 73-81. PMID 2531584 DOI: 10.1016/0006-291X(89)91035-8 |
0.552 |
|
| 1990 |
Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. The Journal of Urology. 143: 742-6. PMID 2313798 DOI: 10.1016/S0022-5347(17)40078-4 |
0.594 |
|
| 1990 |
Matuo Y, Nishi N, Takasuka H, Masuda Y, Nishikawa K, Isaacs JT, Adams PS, McKeehan WL, Sato GH. Production and significance of TGF-β in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma Biochemical and Biophysical Research Communications. 166: 840-847. PMID 2302241 DOI: 10.1016/0006-291X(90)90886-R |
0.431 |
|
| 1990 |
Schulze H, Isaacs JT. Development of hormone refractory tumors: adaption versus clonal selection. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 118: 153-62. PMID 2236837 DOI: 10.1007/978-3-642-83816-3_15 |
0.426 |
|
| 1990 |
Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. The Prostate. 17: 175-87. PMID 2235727 DOI: 10.1002/Pros.2990170302 |
0.5 |
|
| 1990 |
Martikainen P, Isaacs JT. An organ culture system for the study of programmed cell death in the rat ventral prostate. Endocrinology. 127: 1268-77. PMID 2201533 DOI: 10.1210/Endo-127-3-1268 |
0.564 |
|
| 1990 |
Newhall KR, Isaacs JT, Wright GL. Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens Prostate. 17: 317-325. PMID 1701250 DOI: 10.1002/Pros.2990170407 |
0.542 |
|
| 1990 |
Carter BS, Ballantine Carter H, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer Prostate. 16: 187-197. PMID 1691839 DOI: 10.1002/Pros.2990160302 |
0.611 |
|
| 1990 |
Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. The Prostate. Supplement. 3: 1-7. PMID 1689166 DOI: 10.1002/Pros.2990170502 |
0.386 |
|
| 1990 |
Carter HB, Isaacs JT. Why do cells metastasize? World Journal of Urology. 8: 2-5. DOI: 10.1007/Bf01576270 |
0.347 |
|
| 1989 |
Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS. Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. The Prostate. 13: 263-72. PMID 3217275 DOI: 10.1002/Pros.2990130402 |
0.478 |
|
| 1989 |
Henry JM, Isaacs JT. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy. The Journal of Urology. 142: 165-70. PMID 2733098 DOI: 10.1016/S0022-5347(17)38704-9 |
0.408 |
|
| 1989 |
Ramaekers FC, Verhagen AP, Isaacs JT, Feitz WF, Moesker O, Schaart G, Schalken JA, Vooijs GP. Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system. The Prostate. 14: 323-39. PMID 2664736 DOI: 10.1002/Pros.2990140405 |
0.53 |
|
| 1989 |
English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. The Prostate. 15: 233-50. PMID 2555799 DOI: 10.1002/Pros.2990150304 |
0.45 |
|
| 1989 |
Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia The Prostate. Supplement. 2: 33-50. PMID 2482772 DOI: 10.1002/Pros.2990150506 |
0.567 |
|
| 1989 |
Jarow JP, Isaacs JT. Prostatic growth effects of rat urogenital sinus and human prostatic tissue in the rat. The Prostate. 14: 301-8. PMID 2473458 DOI: 10.1002/Pros.2990140403 |
0.523 |
|
| 1988 |
Henry JM, Isaacs JT. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy. The Journal of Urology. 139: 1119-23. PMID 3361656 DOI: 10.1016/S0022-5347(17)42800-X |
0.457 |
|
| 1988 |
Matuo Y, Nishi N, Tanaka H, Sasaki I, Isaacs JT, Wada F. Production of IGF-II-related peptide by an anaplastic cells line (AT-3) established from the dunning prostatic carcinoma of rats In Vitro Cellular & Developmental Biology – Plant. 24: 1053-1056. PMID 3182557 DOI: 10.1007/Bf02620881 |
0.359 |
|
| 1988 |
Isaacs JT, Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. The Prostate. 13: 165-88. PMID 3174494 DOI: 10.1002/Pros.2990130208 |
0.546 |
|
| 1988 |
Treiger B, Isaacs J. Expression of a Transfected v-Harvey-Ras Oncogene in a Dunning Rat Prostate Adenocarcinoma and the Development of High Metastatic Ability The Journal of Urology. 140: 1580-1586. PMID 3057238 DOI: 10.1016/S0022-5347(17)42131-8 |
0.447 |
|
| 1988 |
Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology. 123: 2124-31. PMID 2901342 DOI: 10.1210/Endo-123-4-2124 |
0.392 |
|
| 1988 |
Kyprianou N, English HF, Isaacs JT. Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. The Prostate. 13: 103-17. PMID 2845374 DOI: 10.1002/Pros.2990130203 |
0.536 |
|
| 1988 |
Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 122: 552-62. PMID 2828003 DOI: 10.1210/Endo-122-2-552 |
0.532 |
|
| 1987 |
English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. The Prostate. 11: 229-42. PMID 3684783 DOI: 10.1002/Pros.2990110304 |
0.507 |
|
| 1987 |
Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. The Prostate. 11: 41-50. PMID 3658827 DOI: 10.1002/Pros.2990110106 |
0.618 |
|
| 1987 |
Kyprianou N, Isaacs JT. Biological significance of measurable androgen levels in the rat ventral prostate following castration. The Prostate. 10: 313-24. PMID 3601809 DOI: 10.1002/Pros.2990100405 |
0.509 |
|
| 1987 |
Nishi N, Matuo Y, Matsui S, Sandberg AA, Isaacs JT, Wada F. Isolation of a 41 kilodalton cytosol protein from the Dunning rat prostatic adenocarcinoma: characterization as depolymerized actin isomers. The Prostate. 10: 303-12. PMID 3601808 DOI: 10.1002/Pros.2990100404 |
0.333 |
|
| 1987 |
Isaacs JT, Kyprianou N. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urological Research. 15: 133-8. PMID 3307086 DOI: 10.1007/Bf00254424 |
0.642 |
|
| 1987 |
Alexander RB, Isaacs JT, Coffey DS. Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer Journal of Urology. 138: 427-429. PMID 3037127 DOI: 10.1016/S0022-5347(17)43178-8 |
0.341 |
|
| 1987 |
Schulze H, Isaacs J, Senge T. Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. The Journal of Urology. 137: 909-11. PMID 2952809 DOI: 10.1016/S0022-5347(17)44292-3 |
0.512 |
|
| 1987 |
Kyprianou N, Isaacs JT. Biological Significance of Measurable Dihydrotestosterone (DHT) Levels in the Prostate Following Castration Journal of Urology. 137. DOI: 10.1016/S0022-5347(17)75248-2 |
0.57 |
|
| 1987 |
Isaacs J, Isaacs W, Feitz W, Scheres J. Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting Metastatic Abilities of Prostatic Cancers Journal of Urology. 137: 1314-1314. DOI: 10.1016/S0022-5347(17)44497-1 |
0.618 |
|
| 1986 |
Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. The Prostate. 9: 261-81. PMID 3774632 DOI: 10.1002/Pros.2990090306 |
0.561 |
|
| 1986 |
Jarow JP, Marshall FF, Isaacs JT. A chicken chorioallantoic membrane assay for the evaluation of the androgen responsiveness of prostatic tissue. The Journal of Urology. 135: 1312-8. PMID 2423713 DOI: 10.1016/S0022-5347(17)46082-4 |
0.566 |
|
| 1985 |
Brendler CB, Follansbee AL, Isaacs JT. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. The Journal of Urology. 133: 495-501. PMID 3856037 DOI: 10.1016/S0022-5347(17)49040-9 |
0.474 |
|
| 1985 |
Isaacs J. Antagonistic Effect of Androgen on Prostatic Cell Death Journal of Urology. 133: 553-553. DOI: 10.1016/S0022-5347(17)49083-5 |
0.607 |
|
| 1984 |
Brendler CB, Isaacs JT, Follansbee AL, Walsh PC. The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. The Journal of Urology. 131: 694-700. PMID 6708184 DOI: 10.1016/S0022-5347(17)50585-6 |
0.404 |
|
| 1984 |
Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. The Prostate. 5: 1-17. PMID 6694914 DOI: 10.1002/Pros.2990050102 |
0.472 |
|
| 1984 |
Berry SJ, Isaacs JT. Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. Endocrinology. 114: 511-20. PMID 6581042 DOI: 10.1210/Endo-114-2-511 |
0.586 |
|
| 1984 |
Isaacs JT. Antagonistic effect of androgen on prostatic cell death. The Prostate. 5: 545-57. PMID 6483690 DOI: 10.1002/Pros.2990050510 |
0.629 |
|
| 1983 |
Isaacs JT. Prostatic structure and function in relation to the etiology of prostatic cancer. The Prostate. 4: 351-66. PMID 6866850 DOI: 10.1002/Pros.2990040405 |
0.624 |
|
| 1983 |
Isaacs JT. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle. Journal of Steroid Biochemistry. 18: 749-57. PMID 6191128 DOI: 10.1016/0022-4731(83)90255-8 |
0.515 |
|
| 1983 |
Isaacs JT, Brendler CB, Walsh PC. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. The Journal of Clinical Endocrinology and Metabolism. 56: 139-46. PMID 6183287 DOI: 10.1210/Jcem-56-1-139 |
0.56 |
|
| 1983 |
Humphries J, Isaacs J. Unusual Androgen Sensitivity of the Androgen-Independent Dunning R-3327-G Rat Prostatic Adenocarcinoma: Androgen Effect on Tumor Cell Loss Journal of Urology. 130: 1252-1252. DOI: 10.1016/S0022-5347(17)51787-5 |
0.552 |
|
| 1982 |
Gesell MS, Brandes MJ, Arnold EA, Isaacs JT, Ueda H, Millan JC, Brandes D. Retinoic acid binding protein in normal and neopolastic rat prostate. The Prostate. 3: 131-8. PMID 6283503 DOI: 10.1002/Pros.2990030205 |
0.513 |
|
| 1982 |
Elder JS, Isaacs JT, Walsh PC. Androgenic sensitivity of the gubernaculum testis: evidence for hormonal/mechanical interactions in testicular descent. The Journal of Urology. 127: 170-6. PMID 6173493 DOI: 10.1016/S0022-5347(17)53655-1 |
0.382 |
|
| 1981 |
Isaacs JT, Coffey DS. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia Endocrinology. 108: 445-453. PMID 6161001 DOI: 10.1210/Endo-108-2-445 |
0.599 |
|
| 1979 |
Isaacs JT, McDermott IR, Coffey DS. The identification and characterization of a new c1903 steroid metabolite in the eat ventral prostate: 5α-androstane-3β, 6α, 17β-triol Steroids. 33: 639-657. PMID 462504 DOI: 10.1016/0039-128X(79)90114-4 |
0.336 |
|
| Show low-probability matches. |